|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM016979222 |
| 003 |
DE-627 |
| 005 |
20231221070336.0 |
| 007 |
tu |
| 008 |
231221s1991 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0057.xml
|
| 035 |
|
|
|a (DE-627)NLM016979222
|
| 035 |
|
|
|a (NLM)1716407
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Yoshida, O
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical efficacy and safety of long-term administration of YM617 for urinary obstruction of the lower urinary tract
|
| 264 |
|
1 |
|c 1991
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.10.1991
|
| 500 |
|
|
|a Date Revised 30.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The efficacy and safety of YM617, a new alpha 1-blocker, were evaluated in 121 patients with urinary obstruction of the lower urinary tract in the long-term administration study for 1 year. A total of 121 patients, i.e., 111 with benign prostatic hypertrophy (BPH), 6 with bladder neck sclerosis (BNS), 3 with BPH with BNS and 1 with female urinary obstruction, were orally administered 0.1 to 0.4 mg of YM617 once daily. Patients showing improvement of patient's impression and of subjective symptoms judged by the physician were increased until the 16th to 20th week, and it had been maintained there after. Objective findings were improved to a constant level after the 4th week. Patient's impression and subjective symptoms were improved in a certain dose-response relationship Side effects were observed in 3 patients but none were serious. YM617 proved to be useful in the treatment of patients with urinary obstruction of the lower urinary tract like BPH because it maintained the efficacy and safety in the long-term administration
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
7 |
|a Sulfonamides
|2 NLM
|
| 650 |
|
7 |
|a Tamsulosin
|2 NLM
|
| 650 |
|
7 |
|a G3P28OML5I
|2 NLM
|
| 700 |
1 |
|
|a Takeuchi, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hida, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomoyoshi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arai, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okada, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Akino, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Isomatsu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okabe, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fukuyama, T
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 37(1991), 4 vom: 01. Apr., Seite 421-9
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:37
|g year:1991
|g number:4
|g day:01
|g month:04
|g pages:421-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 37
|j 1991
|e 4
|b 01
|c 04
|h 421-9
|